It will re-rate4 Jun 2020 11:03
at some point, FDA approval and Sales will bring some stability to the share. I think one reason we aren't see the rise sooner is the placing and the way it was done really did spook a lot of pi and so the core base of pi investors in this share is lower than those in AVCT and NYCT. AVCT had a placing today, which showed their CEO lied to them and yet with no product yet available, a placing and no indication who is do the development on their product at current time still the pi's are investing into it and it is still in positive percentage for the day so far.
There is a core group of people on this bulletin board, all scratching their heads at the moment stumped why the price is not higher given our low market cap and product actually available and CE approved. Where are all the other investors who would normally be piling in on such a strong future with a proven product. It's simply the case that the placing did a lot more damage than just a reasonable amount of shares on the market, the real issue is getting people to have trust in the company. Once that returns that is what will re-rate the share, as the product is classed as a gold standard so the fundamentals will win over.